Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOT plus tislelizumab for oligometastatic gastric adenocarcinoma
ChiCTR2200064425Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, fluorouracil, folinic acid, oxaliplatin and docetaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sun Yat-sen University. Primary endpoint: R0 resection rate. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
tislelizumabfluorouracilfolinic acidoxaliplatindocetaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200064425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064425.